GlassScriptPhysician profile
Mousa R Bateh
NPI 1184623555
$3,812.45
in general payments reported to CMS, 2019-2025
24 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Primary Podiatric Medicine provider received nationally (typical 2025 total: $232).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,076 · 2020: $228 · 2021: $179 · 2022: $417 · 2023: $487 · 2024: $269 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $911.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tosoh Bioscience, INC. | $1,566.00 | 2019 | |
| Organogenesis INC. | $404.01 | 2019-2022 | |
| Abbott Laboratories | $349.38 | 2021-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $349.29 | 2022-2024 | Afrezza |
| Novo Nordisk INC | $202.34 | 2019-2023 | Wegovy |
| Orthofix Medical, INC. | $155.06 | 2020 | |
| Medtronic, INC. | $147.21 | 2022-2025 | Minimed 780g, Intellis Adaptivestim |
| Xeris Pharmaceuticals, INC. | $68.26 | 2021-2024 | Recorlev |
| Ibsa Pharma INC. | $64.72 | 2022-2023 | Tirosint, Licart |
| Alexion Pharmaceuticals, INC. | $59.49 | 2023-2025 | Strensiq |
| Lilly USA, LLC | $58.97 | 2023-2025 | Jardiance, Mounjaro, Baqsimi |
| Smith+Nephew, INC. | $58.00 | 2025 | Collagenase Santyl |
| Corcept Therapeutics | $55.73 | 2022-2023 | Korlym |
| Amgen INC. | $52.79 | 2023-2024 | Tepezza, Evenity, Prolia |
| Lifescan, INC. | $32.03 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $27.75 | 2019 | |
| Radius Health, INC. | $27.33 | 2025 | |
| Janssen Pharmaceuticals, INC | $24.34 | 2019 | |
| Eusa Pharma (US) LLC | $22.68 | 2022 | |
| Recordati_rare_diseases_inc. | $22.68 | 2022 | |
| Dexcom, INC. | $18.85 | 2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.29 | 2019 | |
| Tandem Diabetes Care, INC. | $14.00 | 2019 | |
| Nevro Corp. | $13.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mousa Bateh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.